Harnessing adjuvant-induced epigenetic modulation for enhanced immunity in vaccines and cancer therapy

Adjuvants are crucial in vaccines and cancer therapies, enhancing therapeutic efficacy through diverse mechanisms. In vaccines, adjuvants are traditionally valued for amplifying immune responses, ensuring robust and long-lasting protection against pathogens. In cancer treatments, adjuvants can boost...

Full description

Saved in:
Bibliographic Details
Main Authors: Yasmine Megdiche, Rosângela Salerno-Gonçalves
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-02-01
Series:Frontiers in Immunology
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2025.1547213/full
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850024342068396032
author Yasmine Megdiche
Rosângela Salerno-Gonçalves
author_facet Yasmine Megdiche
Rosângela Salerno-Gonçalves
author_sort Yasmine Megdiche
collection DOAJ
description Adjuvants are crucial in vaccines and cancer therapies, enhancing therapeutic efficacy through diverse mechanisms. In vaccines, adjuvants are traditionally valued for amplifying immune responses, ensuring robust and long-lasting protection against pathogens. In cancer treatments, adjuvants can boost the effectiveness of chemotherapy or immunotherapy by targeting tumor antigens, rendering cancer cells more vulnerable to treatment. Recent research has uncovered new molecular-level effects of the adjuvants, mainly through epigenetic mechanisms. Epigenetics encompasses heritable modifications in gene expression that do not alter the DNA sequence, impacting processes such as DNA methylation, histone modification, and non-coding RNA expression. These epigenetic changes play a pivotal role in regulating gene activity, influencing immune pathways, and modulating the strength and duration of immune responses. Whether in vaccines or cancer treatments, understanding how adjuvants interact with epigenetic regulators offers significant potential for developing more precise, cell-targeted therapies across various medical fields. This review delves into the evolving role of adjuvants and their interactions with epigenetic mechanisms. It also examines the potential of harnessing epigenetic changes to enhance adjuvant efficacy and explores the novel use of epigenetic inhibitors as adjuvants in therapeutic settings.
format Article
id doaj-art-53ea86cd99ff455d84f96e29916765a4
institution DOAJ
issn 1664-3224
language English
publishDate 2025-02-01
publisher Frontiers Media S.A.
record_format Article
series Frontiers in Immunology
spelling doaj-art-53ea86cd99ff455d84f96e29916765a42025-08-20T03:01:07ZengFrontiers Media S.A.Frontiers in Immunology1664-32242025-02-011610.3389/fimmu.2025.15472131547213Harnessing adjuvant-induced epigenetic modulation for enhanced immunity in vaccines and cancer therapyYasmine MegdicheRosângela Salerno-GonçalvesAdjuvants are crucial in vaccines and cancer therapies, enhancing therapeutic efficacy through diverse mechanisms. In vaccines, adjuvants are traditionally valued for amplifying immune responses, ensuring robust and long-lasting protection against pathogens. In cancer treatments, adjuvants can boost the effectiveness of chemotherapy or immunotherapy by targeting tumor antigens, rendering cancer cells more vulnerable to treatment. Recent research has uncovered new molecular-level effects of the adjuvants, mainly through epigenetic mechanisms. Epigenetics encompasses heritable modifications in gene expression that do not alter the DNA sequence, impacting processes such as DNA methylation, histone modification, and non-coding RNA expression. These epigenetic changes play a pivotal role in regulating gene activity, influencing immune pathways, and modulating the strength and duration of immune responses. Whether in vaccines or cancer treatments, understanding how adjuvants interact with epigenetic regulators offers significant potential for developing more precise, cell-targeted therapies across various medical fields. This review delves into the evolving role of adjuvants and their interactions with epigenetic mechanisms. It also examines the potential of harnessing epigenetic changes to enhance adjuvant efficacy and explores the novel use of epigenetic inhibitors as adjuvants in therapeutic settings.https://www.frontiersin.org/articles/10.3389/fimmu.2025.1547213/fulladjuvantepigeneticvaccinecancer therapyimmunityhuman
spellingShingle Yasmine Megdiche
Rosângela Salerno-Gonçalves
Harnessing adjuvant-induced epigenetic modulation for enhanced immunity in vaccines and cancer therapy
Frontiers in Immunology
adjuvant
epigenetic
vaccine
cancer therapy
immunity
human
title Harnessing adjuvant-induced epigenetic modulation for enhanced immunity in vaccines and cancer therapy
title_full Harnessing adjuvant-induced epigenetic modulation for enhanced immunity in vaccines and cancer therapy
title_fullStr Harnessing adjuvant-induced epigenetic modulation for enhanced immunity in vaccines and cancer therapy
title_full_unstemmed Harnessing adjuvant-induced epigenetic modulation for enhanced immunity in vaccines and cancer therapy
title_short Harnessing adjuvant-induced epigenetic modulation for enhanced immunity in vaccines and cancer therapy
title_sort harnessing adjuvant induced epigenetic modulation for enhanced immunity in vaccines and cancer therapy
topic adjuvant
epigenetic
vaccine
cancer therapy
immunity
human
url https://www.frontiersin.org/articles/10.3389/fimmu.2025.1547213/full
work_keys_str_mv AT yasminemegdiche harnessingadjuvantinducedepigeneticmodulationforenhancedimmunityinvaccinesandcancertherapy
AT rosangelasalernogoncalves harnessingadjuvantinducedepigeneticmodulationforenhancedimmunityinvaccinesandcancertherapy